Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival
Conclusion Concurrent chemoradiotherapy using weekly cisplatin at 40mg/m2 per week is an effective, well tolerated regimen allowing most patients to receive at least 5 cycles of chemotherapy. However, a phase III randomized control trial comparing the standard dose of 100mg/m2 cisplatin tri-weekly with a weekly regimen is needed to establish the long term clinical outcome. [...] Thieme Publicações Ltda Rio de Janeiro, BrazilArticle in Thieme eJournals: Table of contents | Abstract | open access Full text
Source: International Archives of Otorhinolaryngology - Category: ENT & OMF Authors: Iqbal, Muhammad Shahid Chaw, Cheng Kovarik, Josef Aslam, Shahzeena Jackson, Aaron Kelly, John Dobrowsky, Werner Kelly, Charles Tags: Original Research Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Dermatitis | Dermatology | ENT & OMF | Head and Neck Cancer | Hospital Management | Hypopharyngeal Cancer | Laryngeal Cancer | Nasopharyngeal Cancer | Oral Cancer | Oral Cavity Cancer | Oropharyngeal Cancer | Pain | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology